This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCormick, D. L. Articles by Kelloff, G. J. Search for Related Content PubMed PubMed Citation Articles by McCormick, D. L. Articles by Kelloff, G. J.

Exceptional Chemopreventive Activity of Low-Dose Dehydroepiandrosterone in the Rat Mammary Gland¹

Life Sciences Department. IIT Research Institute, Chicago, Illinois 60616 [D. L. M., K. V. N. R., W. D. J., T. A. B-G.], and Chemoprevention Investigational Studies Branch, National Cancer Institute, Bethesda, Maryland 20852 [V. E. S., R. A. L., G. J. K.]

To determine if the chemopreventive activity of dehydroepiandrosterone (DHEA) in the rat mammary gland can be dissociated from its toxicity, two studies were conducted in which low doses of DHEA were administered alone and in combination with other agents to rats treated with N-methyl-N-nitrosourea. Beginning 1 week prior to administration of 35 mg N-methyl-N-nitrosourea per kg body weight, groups of 20 female Sprague-Dawley rats were fed AIN-76A diet supplemented with DHEA alone (800 or 400 mg/kg diet), DHEA + tamoxifen (80 or 40 µg/kg diet), DHEA + carbenoxolone (3500 or 1750 mg/kg diet), or DHEA + tamoxifen + carbenoxolone. When administered alone at either 800 or 400 mg/kg diet, DHEA reduced mammary cancer incidence from >70% in dietary controls to 0%; mammary cancer incidence in all DHEA combination regimens was also 5%. The dose levels of DHEA used induced no toxicity or alteration in body weight gain. These results indicate that dietary supplementation with low doses of DHEA has chemopreventive efficacy greater than or equal to that of endocrine ablation. This protection may be mediated by the induction of differentiation in the mammary parenchyma.

¹ Research supported by contract N01-CN-85097-11 and Grant CA-30646 from the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Life Sciences Department, IIT Research Institute, 10 West 35th Street, Chicago, IL 60616.

Received 1/22/96. Accepted 2/29/96.

This article has been cited by other articles:

				D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis, February 1, 2007; 28(2): 398 - 403. [Abstract] [Full Text] [PDF]

				F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]

				H. P. Ciolino, C. J. MacDonald, and G. C. Yeh Inhibition of Carcinogen-activating Enzymes by 16{alpha}-Fluoro-5-androsten-17-one Cancer Res., July 1, 2002; 62(13): 3685 - 3690. [Abstract] [Full Text] [PDF]

				K. P. Nephew, E. Osborne, R. A. Lubet, C. J. Grubbs, and S. A. Khan Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat Experimental Biology and Medicine, March 1, 2000; 223(3): 288 - 294. [Abstract] [Full Text]

				H. P. Ciolino and G. C. Yeh The Steroid Hormone Dehydroepiandrosterone Inhibits CYP1A1 Expression in Vitro By a Post-transcriptional Mechanism J. Biol. Chem., December 3, 1999; 274(49): 35186 - 35190. [Abstract] [Full Text] [PDF]

				K. V. N. Rao, W. D. Johnson, M. C. Bosland, R. A. Lubet, V. E. Steele, G. J. Kelloff, and D. L. McCormick Chemoprevention of Rat Prostate Carcinogenesis by Early and Delayed Administration of Dehydroepiandrosterone Cancer Res., July 1, 1999; 59(13): 3084 - 3089. [Abstract] [Full Text] [PDF]